These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33721950)

  • 1. [Indications and efficacy of neoadjuvant therapy for pancreatic cancer].
    Gou SM; Wu HS
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):716-721. PubMed ID: 33721950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Current consensus and controversy in neoadjuvant therapy for pancreatic cancer].
    Ou ZL; Li YX; Ji LD; Ke MJ
    Zhonghua Wai Ke Za Zhi; 2020 Feb; 58(2):99-104. PubMed ID: 32074807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoadjuvant treatment of primarily resectable and borderline resectable pancreatic cancer].
    Scheufele F; Friess H
    Chirurg; 2020 May; 91(5):391-395. PubMed ID: 31965198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
    Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
    BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New developments in the management of borderline resectable pancreatic cancers.
    Goodman MD; McPartland S; Huber K; Saif MW
    JOP; 2013 Jul; 14(4):334-6. PubMed ID: 23846921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
    Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of extended surgery for pancreatic cancer in the context of neoadjuvant therapy].
    Zhang TP; Liu YZ; Cao Z
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):481-485. PubMed ID: 32610414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer.
    Lutz MP; Zalcberg JR; Ducreux M; Aust D; Bruno MJ; Büchler MW; Delpero JR; Gloor B; Glynne-Jones R; Hartwig W; Huguet F; Laurent-Puig P; Lordick F; Maisonneuve P; Mayerle J; Martignoni M; Neoptolemos J; Rhim AD; Schmied BM; Seufferlein T; Werner J; van Laethem JL; Otto F
    Eur J Cancer; 2017 Jul; 79():41-49. PubMed ID: 28460245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances and challenges of neoadjuvant therapy in pancreatic cancer.
    Yu Y; Zheng P; Chen Y; Wang B; Paul ME; Tao P; Wang D; Li H; Gu B; Gao L; Wang D; Chen H
    Asia Pac J Clin Oncol; 2021 Dec; 17(6):425-434. PubMed ID: 33164329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOLFIRINOX-based neoadjuvant therapy in borderline resectable or unresectable pancreatic cancer: a meta-analytical review of published studies.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Aitini E; Barni S;
    Pancreas; 2015 May; 44(4):515-21. PubMed ID: 25872127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Challenges and stratigies of neoadjuvant therapy for pancreatic cancer].
    Zhang TP; Luo WH; Qiu JD
    Zhonghua Yi Xue Za Zhi; 2021 Mar; 101(10):704-707. PubMed ID: 33721947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery.
    Barnes CA; Chavez MI; Tsai S; Aldakkak M; George B; Ritch PS; Dua K; Clarke CN; Tolat P; Hagen C; Hall WA; Erickson BA; Evans DB; Christians KK
    Surgery; 2019 Sep; 166(3):277-285. PubMed ID: 31272811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of neoadjuvant chemotherapy for resectable pancreatic carcinoma].
    Motoi F; Kawaguchi K; Aoki T; Kudo K; Yabuuchi S; Fukase K; Mizuma M; Sakata N; Otsutomo S; Morikawa T; Hayashi H; Nakagawa K; Okada T; Yoshida H; Naitoh T; Katayose Y; Egawa S; Unno M
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1632-6. PubMed ID: 24393872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer].
    Bai XL; Li X; Liang TB
    Zhonghua Wai Ke Za Zhi; 2020 Jul; 58(7):486-489. PubMed ID: 32610415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neoadjuvant therapy in pancreatic cancer: a review.
    Russo S; Ammori J; Eads J; Dorth J
    Future Oncol; 2016 Mar; 12(5):669-85. PubMed ID: 26880384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery.
    Nagakawa Y; Sahara Y; Hosokawa Y; Murakami Y; Yamaue H; Satoi S; Unno M; Isaji S; Endo I; Sho M; Fujii T; Takishita C; Hijikata Y; Suzuki S; Kawachi S; Katsumata K; Ohta T; Nagakawa T; Tsuchida A
    Ann Surg Oncol; 2019 Jun; 26(6):1629-1636. PubMed ID: 30610555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.